Abstract: The invention includes a computer-implemented method, system, and computer-readable medium having computer-executable modules for judging changes in components of an eye. The inventive computer-implemented method includes the steps of acquiring, displaying, and superimposing at least two digital images of the components of the eye. The method further includes the step of processing at least one of the digital images such that the superimposed images may be compared, and the step of flickering among the superimposed digital images. The step of acquiring the images may include the step of converting a photographic representation of the components of the eye to the digital image. The step of processing may include registering, warping, and/or aligning the digital images.

Abstract: The invention includes a computer-implemented method, system, and computer-readable medium having computer-executable modules for judging changes in components of an eye. The inventive computer-implemented method includes the steps of acquiring, displaying, and superimposing at least two digital images of the components of the eye. The method further includes the step of processing at least one of the digital images such that the superimposed images may be compared, and the step of flickering among the superimposed digital images. The step of acquiring the images may include the step of converting a photographic representation of the components of the eye to the digital image. The step of processing may include registering, warping, and/or aligning the digital images.

Abstract: The invention includes a computer-implemented method, system, and computer-readable medium having computer-executable modules for judging changes in components of an eye. The inventive computer-implemented method includes the steps of acquiring, displaying, and superimposing at least two digital images of the components of the eye. The method further includes the step of processing at least one of the digital images such that the superimposed images may be compared, and the step of flickering among the superimposed digital images. The step of acquiring the images may include the step of converting a photographic representation of the components of the eye to the digital image. The step of processing may include registering, warping, and/or aligning the digital images.

Abstract: The invention includes a computer-implemented method, system (100), and computer-readable medium having computer-executable modules for judging changes in components of an eye. The inventive computer-implemented method includes the steps of acquiring (103), displaying (107), and superimposing at least two digital images of the components of the eye. The method further includes the step of processing at least one of the digital images such that the superimposed images may be compared, and the step of flickering among the superimposed digital images. The step of acquiring the images may include the step of converting a photographic representation of the components of the eye to the digital image. The step of processing may include registering, warping, and/or aligning the digital images.

Abstract: The invention includes a computer-implemented method, system (100), and computer-readable medium having computer-executable modules for judging changes in components of an eye. The inventive computer-implemented method includes the steps of acquiring (103), displaying (107), and superimposing at least two digital images of the components of the eye. The method further includes the step of processing at least one of the digital images such that the superimposed images may be compared, and the step of flickering among the superimposed digital images. The step of acquiring the images may include the step of converting a photographic representation of the components of the eye to the digital image. The step of processing may include registering, warping, and/or aligning the digital images.

Abstract: A method for decreasing intraocular pressure by administering an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. These agents, by inhibiting influx or promoting efflux of aqueous humor, can be used to treat glaucoma.

Abstract: The invention relates to a method comprising the step of ocular administration of therapeutically effective amounts of a nicotinic antagonist to control postnatal ocular growth or inhibit the development of myopia.

Abstract: Provided is a method for modulating, controlling or regulating intraocular pressure and secretion of the aqueous humor of the eye, in particular for treating or reducing elevated intraocular pressure or secretion, e.g., related to glaucomas. Selected combined drug therapy effectively and synergistically modulates intraocular pressure by either (1) double-blocking the uptake step, wherein both transporters in the first (entry step) of aqueous humor formation are blocked or inhibited; or (2) blocking the entry and exit steps, wherein the sodium-hydrogen (Na+/H+) exchanger underlying the entry step is blocked or inhibited, and also lowering or reducing the activity of the chloride (Cl−) channels involved in the second (exit) step of aqueous humor formation. By combining the selected drugs or compounds to produce a combined or synergistic modulating effect, control of IOP is achieved at very low concentrations, with fewer adverse side-effects on the patient.

Abstract: This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen.

Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a muscarinic pharmacological antagonist relatively selective for blocking the cholinergic receptors in cells of the brain, neural tissue and/or neural ganglia but less selective for blocking the cholinergic receptors of the cells of smooth muscles at the front of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is pirenzepine. Other suitable antagonists are telenzepine and o-methoxy-sila-hexocyclium.

Abstract: A method of controlling the abnormal postnatal growth of the eye of a maturing animal which comprises the ocular administration of therapeutically effective amounts of a dopamine antagonist.

Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a gamma aminobutyric acid antagonist relatively selective for GABA.sub.B receptors in the cells of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is 2-OH saclofen.

Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a tricyclic compound, said tricyclic compound present in a carrier or diluent suitable for ocular administration. Suitable tricyclics are tertiary amines, secondary amines, and other active metabolites of tricyclic compounds.

Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a gamma aminobutyric acid antagonist relatively selective for GABA.sub.B receptors in the cells of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is 2-OH saclofen.

Abstract: A method of inducing axial elongation of an eye of an animal comprising contacting a first open animal eye with a cholinergic agonist, detecting the change in axial growth of the first eye, applying a known control agent in a second open animal eye, observing the results of the control agent on the second eye, and comparing the change in axial growth of the first eye with the change in axial growth of the second eye.

Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a muscarinic pharmacological antagonist relatively selective for blocking the cholinergic receptors in cells of the brain, neural tissue and/or neural ganglia but less selective for blocking the cholinergic receptors of the cells of smooth muscles at the front of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is pirenzepine. Other suitable antagonists are telenzepine and o-methoxy-sila-hexocyclium.

Abstract: A method of inhibiting the abnormal postnatal axial growth of the eye of a maturing animal during conditions ordinarily leading to said abnormal growth, which comprises (1) determining the neurochemical present in the retina of said eye, eg., dopamine, the concentrations of which is reduced during said conditions, and (2) administering to said eye during post natal maturation effective amounts of said neurochemical, its agonist or its antagonist.

Abstract: Methods for the recovery of bitumen from tar sands comprising the steps of mixing tar sand, solvent and a displacing amount of aqueous medium to form a mixture, followed by separating a bitumen-rich solvent phase from the mixture and recovering bitumen from the bitumen-rich solvent phase are disclosed.

Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a muscarinic pharmacological antagonist relatively selective for blocking the cholinergic receptors in cells of the brain, neural tissue and/or neural ganglia but less selective for blocking the cholinergic receptors of the cells of smooth muscles at the front of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is pirenzepine. Other suitable antagonists are telenzepine and o-methoxy-sila-hexocyclium.

Abstract: A method and composition for inhibition of abnormal postnatal ocular growth are disclosed. The composition comprises vasoactive intestinal peptide (VIP), PHI or a analogue of these peptides. The method for inhibition of abnormal postnatal ocular growth comprises administering to the eye of an animal effective amount of VIP, PHI or analogue of these peptides.